BIOMACS II

(redirected from Biochemical Markers in Acute Coronary Syndromes)

BIOMACS II

Biochemical Markers in Acute Coronary Syndromes. A pilot trial that evaluated the effect of a low-molecular weight heparin (dalteparin), as an adjuvant to thrombolysis in patients with acute MI.
 
Primary endpoints
Proportion of patients with successful reperfusion, recurrent ischemia, patency at 24 hours.

Conclusion
Dalteparin added to streptokinase tended to provide a higher rate of TIMI grade-3 flow in infarct-related artery compared with placebo; there were also fewer recurrent ischaemic episodes 6 to 24 hours after treatment, per Holter monitoring in the dalteparin group.

Logistics
Randomised, placebo-controlled; 101 patients, dalteparin or placebo given just before streptokinase; a second injection of dalteparin or placebo was administered 12 hours after the initial dose.
References in periodicals archive ?
National Academy of Clinical Biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes.
Toward addressing these advances and their impact on biochemical marker utilization in clinical practice, the NACB appointed a chair and members of an LMPG committee that was charged with revising and extending the earlier recommendations by establishing modern guidelines for Utilization of Biochemical Markers in Acute Coronary Syndromes and Heart Failure.
Furthermore, the system evaluated satisfies the requirements specified in IFCC (7) and National Academy of Clinical Biochemistry (9) recommendations for the use of biochemical markers in acute coronary syndrome, thus allowing the simultaneous measurement of early (Myo) and definitive (troponin) markers for the rapid ruling in or out of patients, and of CK-MB when of clinical importance, in relation to hospital policy.
Full browser ?